Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease

Doris Lambracht-Washington
Roger N Rosenberg

Department of Neurology and Neurotherapeutics, Alzheimer’s Disease Center, University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract: Immunotherapy might provide an effective treatment for Alzheimer’s disease (AD). A unique feature of AD immunotherapies is that an immune response against a self-antigen needs to be elicited without causing adverse autoimmune reactions. Current research is focused on two possible targets in this regard. One is the inhibition of accumulation and deposition of amyloid beta 1–42 (Aβ42), which is one of the major peptides found in senile plaques, and the second target is hyperphosphorylated tau, which forms neurofibrillary tangles inside the nerve cell and shows association with the progression of dementia. Mouse models have shown that immunotherapy targeting Aβ42 as well as tau with the respective anti-Aβ or anti-tau antibodies can provide significant improvements in these mice. While anti-Aβ immunotherapy (active and passive immunizations) is already in several stages of clinical trials, tau-based immunizations have been analyzed only in mouse models. Recently, as a significant correlation of progression of dementia and levels of phosphorylated tau have been found, high interest has again focused on further development of tau-based therapies. While Aβ immunotherapy might delay the onset of AD, immunotherapy targeting tau might provide benefits in later stages of this disease. Last but not least, targeting Aβ and tau simultaneously with immunotherapy might provide additional therapeutic effects, as these two pathologies are likely synergistic; this is an approach that has not been tested yet. In this review, we will summarize animal models used to test possible therapies for AD, some of the facts about Aβ42 and tau biology, and present an overview on halted, ongoing, and upcoming clinical trials together with ongoing preclinical studies targeting tau or Aβ42.

Keywords: immunotherapy, prevention trials, active and passive vaccination, tau protein, amyloid precursor protein, Aβ42, neurofibrillary tangles

Introduction

Alzheimer’s disease (AD) is the sixth-leading cause of death in the US, and until now there has been no effective treatment available. Current treatment options are only symptomatic and do not affect disease progression. Immunotherapy in which antibodies directed against the two pathophysiological hallmarks of AD – amyloid plaques with amyloid beta 1–42 (Aβ42) as their major component and neurofibrillary tangles (NFTs) that are formed by hyperphosphorylated tau – are possible targets for an immunotherapeutic intervention. Both pathophysiological features are formed from aberrant self-proteins: a major component of the amyloid plaques is Aβ42, which is a small proteolytic fragment from the amyloid precursor protein (APP) with the tendency to aggregate into insoluble fibrils, and the NFTs are derived from hyperphosphorylation of the protein tau, which makes this protein insoluble and leads to aggregate formation.
and malfunction. Other changes in AD brain include inflammation and oxidative stress. All of these features lead to severe dysfunction, neurodegeneration, and neuron loss, and end-stage brain from AD patients shows a substantial loss in weight compared to brains of age- and sex-matched nondemented individuals. The most neurotoxic form of Aβ is not the solid plaques but the oligomeric forms of Aβ42.

In rodents, a dodecameric form of Aβ42, which was isolated from brains of APP transgenic mice, leads directly to impairment of synaptic plasticity and memory. In humans, the same feature was described for an Aβ42 dimer, which had been isolated from human AD brains. A recent study showed that all of these Aβ42 oligomers, dimers, trimers, and dodecamers (Aβ56) can be isolated from human brain and cerebrospinal fluid (CSF) and Aβ56 levels correlated positively with levels on soluble tau protein in brain from AD patients. The description of Aβ42 aggregation as being outside the nerve cells and tau aggregates being found only inside neurons may not be as strict as proposed. There is evidence that Aβ accumulation occurs first inside the nerve cell and accumulates outside the neurons as disease progresses, and for tau it has also been shown in vitro and in vivo models that extracellular tau aggregates lead to uptake of these aggregates by the nerve cells in which they induce intracellular tau aggregation, and that the injection of insoluble tau, and to a lesser extent the injection of soluble tau, into mouse brains leads to spreading of tau pathology.

**Animal models**

In familial AD (FAD), which accounts for less than 5% of all AD cases, mutations were discovered within the APP gene or in genes encoding enzymes involved in the proteolytic degradation of APP, presenilin (PS)-1 and -2, which increase the amyloidogenic processing of APP, and are thus leading to increased Aβ42 levels. Based on these mutations, transgenic mouse models were developed that recapitulate some of the features seen in humans. Even though not a perfect replica for the human disease, the mouse models were helpful in discovering mechanisms by which Aβ oligomers and tau oligomers were directly leading to dysfunction and toxicity. These mouse models also showed that immunotherapy can modify the development of disease. In experiments for Aβ42 immunotherapy, most often used is a double transgenic mouse, which carries a chimeric mouse/human amyloid precursor protein gene (Mo/HuAPP695 Swe) and the gene for mutant human PS1 (PS1-dE9), which are expressed under regulation from different strong promoter sequences, such as the prion protein, platelet-derived growth factor, or the Thy-1 promoter. These transgenic mice develop Aβ42 deposits and senile plaques in the brain by 6–7 months of age. While there have been no tau mutations observed in AD, a mutated human tau gene (P301S or P301L) has been associated with forms of frontotemporal dementia with tangle pathology. Mice transgenic for this particular human gene provide tools to study tau pathology and tangle-related neurodegeneration, as well as the evaluation of potential therapies. These mice show the age-dependent development of NFTs, and develop progressive motor dysfunctions correlating with the loss of motor neurons in later stages. A triple-transgenic mouse model, which combines Aβ and Tau pathology carrying the mutated human APP and mutated human microtubule-associated protein tau (MAPT) gene, and even a quintuple-transgenic mouse model (5 × FAD) that combines three APP and two PS1 FAD mutations has been generated in an effort to make this model more complete. An important new animal model was recently described in the rat. Rats transgenic for human APPs and the mutant human PS1 (PS1-dE9) genes developed many of the characteristic features of AD: amyloid plaques, tau tangles, and memory deficits, as well as loss of neurons and neurodegeneration. Different from the mouse models, rats developed the NFTs “naturally,” which is in strong support of the order of the pathophysiological findings: Aβ accumulation first, followed by tangle formation. The explanation for this important difference from the mouse models is that the tau proteome is much closer to the human tau proteome than mouse tau. While the mouse expresses only three different tau isoforms in the brain, which is due to the lack of exon 10 splicing, the rat expresses the same six tau protein isoforms that are found in human brain.

**Amyloid precursor protein**

APP is a type 1 transmembrane protein with a large extracellular domain and a short intracellular segment that is expressed in many tissues, with the highest expression level in the brain. A role for APP in neural tissue is synaptic formation and repair; APP expression is upregulated during differentiation and after neural injury. Depending on whether APP is processed via the α-secretase or the β-secretase pathway, the products are nonamyloidogenic or amyloidogenic, respectively. The aforementioned mutations within the APP gene, which cause FAD, have been found to dramatically increase production of Aβ42. Recently, a new mutation within the APP gene was described that showed protection against AD. The APP substitution A673T is adjacent to the β-secretase cleavage site, leading to a 40% reduction in overall Aβ42 levels. These
findings strongly support the amyloid-cascade hypothesis, which was postulated more than 20 years ago that posits that Aβ accumulation, while it may not be the initial event, plays a central role in the multifactorial pathogenesis of AD.28-31

**Clinical human studies: anti-Aβ immunization**

Following the observations that Aβ42 accumulation in brain is strongly associated with the development of AD, immunizations against Aβ were tested in AD mouse models. Results showed that this treatment can indeed lead to reduction of total amyloid levels in brain, as well as removal of the senile plaques. Most importantly, a significant effect from the immunotherapy had been shown on mouse memory and performance in behavioral tests.14,32-34

The first clinical trial, AN1792, in which AD patients received Aβ42 peptide injections to induce an antibody immune response, was stopped when 6% of the treated patients developed meningoencephalitis.35-37 But besides the negative side effect, it appeared that Aβ42 immunotherapy had worked in regard to reduction of overall Aβ42 and plaque counts in the brains of immunized patients, even though it did not stop the progression of dementia.38 As immunotherapy has great potential as a disease-modifying intervention in contrast to the currently available symptom-only treatment options, major efforts are in progress to make this therapy for AD safe and effective, and a number of active and passive immunotherapies targeting Aβ peptides are currently in clinical trials.

Based on the observed negative side effect from AN1792 with autoimmune T-cell responses, all of the active immunization trials are now concentrated on the B-cell epitope (Aβ1–6 or Aβ1–15) to produce antibodies while avoiding a possible inflammatory T-cell response. Three of these epitope peptide vaccines for active immunizations – CAD106, (Novartis, Basel, Switzerland), ACC-001 (Elan Corporation, Dublin, Ireland), and Affitope (Affiris AG, Vienna, Austria) – are currently in phase II clinical trials. In the CAD106 vaccine, Aβ1–6 is coupled to a heterologous carrier protein to optimize an immune response, and in the Affitope vaccine, a peptide is used that mimics the Aβ B-cell epitope but has no sequence similarities.39-41 Positive antibody titers and no adverse autoimmune inflammation has been found in clinical trials using these new epitope vaccines. New results were also recently reported from mouse studies using very similar constructed epitope peptide vaccines for potential use in AD patients.42,43

The most promising approach for AD immunotherapy is currently passive immunization with humanized anti-Aβ antibodies. In this approach, preformed anti-Aβ42 antibodies are injected intravenously (IV) with the goal that these antibodies will help to reduce amyloid burden in the brain of AD patients by several possible mechanisms, such as facilitation of phagocytosis of amyloid by microglia, inhibition of amyloid aggregation, or binding of antibodies to amyloid in blood causing a concentration gradient with net efflux of Aβ42 from brain. Observed complications from the injection with some of the monoclonal antibodies (mAbs) is that they show a tendency to cause vasogenic edema and brain microhemorrhage, which have been reported also in mouse models.44-46 Three of the monoclonal antibody therapies – solanezumab from Eli Lilly and Company (Indianapolis, IN, USA), crenezumab from Genentech, (San Francisco, CA, USA), and gantenerumab from Hoffmann-La Roche (Basel, Switzerland) – are in phase II and III clinical trials and ongoing.47-52 A fourth antibody trial, investigating bapineuzumab from Pfizer, (New York, NY, USA), which was completed in 2012, was discontinued when the results obtained did not meet the predicted results.53

Solanezumab and crenezumab are humanized mouse mAbs detecting a mid-region Aβ epitope, Aβ13–28, and Aβ12–23. Solanezumab has a good safety profile, and showed in patients with mild AD the slowing of cognitive decline compared with placebo by one-third.54 An increase of Aβ42 levels in CSF might indicate that this antibody, which binds preferentially soluble forms of Aβ, has the ability to mobilize Aβ from brain amyloid depositions.50 The mAb crenezumab was further modified to carry a certain human immunoglobulin (Ig)-G isoform, IgG4, which is a Th2 antibody isotype carrying noninflammatory features such as reduced Fc-receptor binding on other immune cells. Indeed, results from a phase I clinical trial showed that patients treated with crenezumab showed less brain microhemorrhage and vasogenic edema compared to published observations from other antibody immunotherapy studies.47,51 Gantenerumab is a fully human monoclonal IgG1 antibody detecting two separate epitopes in Aβ42 (Aβ3–11 and Aβ19–28), and it has been reported that this antibody does not bind soluble Aβ but only the fibrillar forms of Aβ. In vitro studies showed that gantenerumab can induce phagocytosis of Aβ fibrils by brain microglia.48 In patients, a decrease of brain amyloid was found in an antibody dose-dependent manner by up to 30%, as shown by positron emission tomography (PET) scans with the fibrillar Aβ-specific Pittsburgh B compound.52

Another drug to treat AD with anti-Aβ antibodies, Gammagard from Baxter International (Deerfield, IL,
USA), which is in phase III clinical trials and had shown favorable results to some extent, has failed to meet primary end points such as the slowing of cognitive and functional decline in treated AD patients, and is thus under debate whether trials of it will continue. In this study, patients with mild-to-moderate AD received injections of concentrated Ig (IVIg) from healthy persons to utilize naturally occurring autoantibodies that specifically recognize and block the toxic effects of Aβ (nAbs-Aβ). The level of anti-Aβ antibodies in the serum from AD patients increased in proportion to the IVIg dose administered, and CSF Aβ decreased significantly at 6 months of continued treatment, then returned to baseline when treatment was stopped, and decreased again with continuous IVIg treatment, indicating that the naturally occurring anti-Aβ antibodies mobilized Aβ from brain. Mini-mental state scores increased an average of 2.5 points with 6 months of treatment and remained stable with treatment was continued. In a phase II dose-finding clinical study performed in the US and Germany in which AD patients also received IVIg injections (Octagam®, Octapharma, Toronto, ON, Canada), the main focus was on the safety profile of this therapy. In the 6-month treatment period, 14% of patients showed brain microbleeds and one patient had an ischemic stroke, both of which are known side effects of IVIg therapy. The conclusion from this trial was that IVIg has tolerable safety and that further studies with larger patient cohorts and longer treatment times are needed to draw decisive conclusions.

**New AD-prevention trials**

One of the main arguments for the lack of more definitive positive results from clinical trials in AD is that the treatment was started too late. It has been shown that Aβ42 concentrations in CSF decline 25 years before the onset of clinical symptoms, which indicates Aβ deposition in brain, and 15 years before clinical symptoms are noticeable; these fibrillar Aβ deposits are visible in PET scans with fibrillar Aβ-specific Pittsburgh compound B. Thus, a likely effective prevention and/or intervention have to start much earlier and in patients which do not already show symptoms for AD.

Three major prevention trials are slated to start in 2013: (1) the DIAN (Dominantly Inherited Alzheimer Network) study, (2) the Alzheimer’s Prevention Initiative (API) study, and (3) the Anti-Amyloid Treatment of Asymptomatic Alzheimer’s Disease (A4) study. These studies will focus on therapy in patient cohorts before the onset of clinical symptoms of AD.

The DIAN study will be undertaken in patients who are highly likely to develop AD at an early age, as these patients are carriers of genetic mutations that cause FAD. Treatment methods will be immunotherapy with two anti-Aβ mAbs, solanezumab and gantenerumab, and as a different treatment option a β-secretase inhibitor (LY2886721 from Lilly) will be used, which reduces Aβ deposition, as this reagent blocks the β-secretase enzyme involved in APP turnover on the cell surface. Also the API study will be undertaken in FAD patients: a large group of FAD carriers in Colombia which will develop AD early with end-stage dementia around the age of 50 years, which is decades earlier than the typical sporadic AD case. In the API study, the patients will receive passive immunizations with the mAb crenezumab. The A4 study will focus on the most often found form of AD, which is sporadic AD. Enrollment groups for this trial are older patients who are not genetic carriers, but already show early stages of Aβ deposition in the brain as measured by PET scan. In this study, passive immunotherapy will be done with the mAb solanezumab, which binds soluble Aβ, and the hope is that this early treatment will clearly show that treatment before the occurrence of clinical symptoms will lead to better benefits by blocking Aβ accumulation and delay the onset of AD.

**Other alternatives for active Aβ immunotherapy**

DNA immunizations differ in many ways from peptide immunizations, and in the search for alternative active immunization therapies, many groups, including ourselves, are investigating this vaccination route. In DNA immunizations, the DNA encoding the respective antigen is injected into skin or muscle. The DNA is then transcribed and expressed at the injection site. Local dendritic cells will take up the antigen, migrate to local lymph nodes, and present the protein to circulating lymphocytes, thereby initiating a general immune response. Our reports on the effectiveness of DNA Aβ42 immunization in the AD transgenic mouse model were the first to show that Aβ42 levels in the brain were reduced by 41% and Aβ42-containing plaques reduced by 50%. Similar findings were described by others in later studies.

Figure 1 shows the results from two groups of DNA Aβ42 trimer-immunized APP/PS1 double-transgenic mice and the respective control DNA (luciferase [Luc])-immunized mice (our group, unpublished results). These mice had been immunized eleven times with DNA Aβ42 trimer or Luc DNA, respectively, via gene gun starting at 4 months of age. The
mice in group A had been analyzed 14 days following the final immunization, while the mice in group B were analyzed 4 months following the final immunization. The graphs show a comparison of anti-Aβ42 antibody levels (Figure 1A, C, and D) and total Aβ42 peptide levels in the brains from these mice (Figure 1B and E). Data shown were obtained by enzyme-linked immunosorbent assay (ELISA) experiments (plates coated with Aβ42 peptide for detection of the anti-Aβ42 antibodies or coated with an anti-Aβ42 antibody for detection of Aβ42 in a sandwich ELISA protocol). In both groups, the Aβ42 levels in brain from the DNA Aβ42 trimer-immunized mice were significantly reduced in comparison to Luc DNA-immunized control animals. In Figure 1B, the Aβ42 levels were reduced 60% compared to the parallel Luc-immunized control mice (9.795 ± 1.455 μg Aβ42 peptide per gram of brain tissue in control mice was reduced to 3.418 ± 0.418 μg Aβ42 peptide in DNA Aβ42-immunized mice), while in Figure 1E the Aβ42 levels were reduced by 25% (48.16 ± 2.914 μg Aβ42 peptide per gram of brain tissue in control mice was reduced to 36.55 ± 1.964 μg Aβ42 peptide in DNA Aβ42-immunized mice). Both these findings were highly significant, with P-values of 0.0006 and 0.0071, respectively. An explanation for this difference is in the time intervals between the final immunizations and the respective analyses of Aβ brain levels. While the mice in group A were still actively producing new antibodies (Aβ42 antibody levels in plasma and Aβ42 peptide levels in brain were shown 14 days after final immunization), in group B, Aβ42 reduction in brain was analyzed 4 months after the final immunization. Consistent with this, total Aβ42 levels in brains were much higher in group B with mean values of 48.2 μg/g wet brain tissue in the control mice compared to 9.7 μg/g wet brain tissue in control mice.
tissue in the control mice of group A, in line with the marked increase of Aβ pathology with an age difference of 4 months (group A was 12 months of age, group B 16 months of age). The anti-Aβ antibody plasma levels were markedly reduced after a 4-month period without booster immunizations in direct comparison to the antibody levels 14 days postimmunization (Figure 1C, \( P = 0.0125 \)), but even with the reduced antibody levels in plasma, the reduction of Aβ42 brain levels was still significantly different from the Luc DNA-immunized control mice (Figure 1E), and this was shown with the much higher levels of total Aβ42 in brain (compare 10 µg/g in 12-month-old mice [Figure 1B] and 48.2 µg/g wet brain tissue in 16-month-old Luc immunized control mice [Figure 1E]) showing that DNA Aβ42 immunotherapy is effective.

DNA immunization differs quantitatively and qualitatively from peptide immunizations, and we and others have shown that Aβ42 DNA vaccination using a gene-gun approach results in a polarized Th2 immune response.\textsuperscript{55,68–72} In our comparisons of DNA and peptide immunizations, we found that in vitro cell proliferation of potentially inflammatory Aβ42-specific T cells was absent in full-length DNA Aβ42 trimer-immunized mice, making this approach effective and safe for possible immunotherapy in AD patients.\textsuperscript{73,74}

**Biological role of tau protein**

Tau is a highly soluble cytoplasmic protein that is primarily found in the brain and functions in neurite outgrowth, axonal transport, and microtubule assembly and stability. Neuronal development requires dynamic microtubules with axonal elongation and shortening, while in differentiated neurons the microtubules are relatively stable, and tau participates in these processes by microtubule binding. Alternative splicing and tau phosphorylation allow all these different functions from a single gene. Six isoforms as the result of alternative splicing of the 13 exons encoded by the MAPT gene are found in the human brain, and all of them are likely to have a specific role as they are differently expressed during development. Tau proteins differ by having three (3R) or four (4R) microtubule-binding repeats of 31–32 amino acids each, and possessing one, two, or no amino terminal inserts of 29 amino acids each (36.8–45.9 kDa). Alternative splicing of exon 10 results in the 3R and 4R isoforms. Tau phosphorylation on specific sites modulates function and intracellular localization. Hyperphosphorylated tau protein dissociates from the neuronal microtubule cytoskeleton, leading to microtubule destabilization and the formation of paired helical filaments (PHFs), which precipitate and become visible tangles.\textsuperscript{75} Furthermore, nonfunctional tau sequesters normally phosphorylated tau proteins, preventing them from binding to microtubules and leading to more dysfunction.

While certain sites are phosphorylated early, such as Ser202 (detected with monoclonal antibody mAb AT8) and Ser235 (mAb AT180), other sites, Ser422 and Ser396/S404 (mAb PHF1), were phosphorylated later in more advanced stages of the disease.\textsuperscript{76}

**Anti-tau immunizations in mouse models**

NFTs are associated with two neurodegenerative diseases: AD and frontotemporal dementia. In AD, NFTs form later in the disease following Aβ42 accumulation, while in frontotemporal dementia no Aβ42 accumulation is present.

Passive and active immunizations against tau have been analyzed in mice using several different mouse strains, as well as different phosho-tau peptides for active immunizations and anti-tau antibodies for passive immunotherapy.\textsuperscript{77–85} In the first report on results from immunizations with a 30-amino acid-long phosphorylated tau peptide, an effect on the ratios of soluble and insoluble tau, reduction of tangle formation in the immunized mice, and functional benefits observed in behavior testing for these mice were shown.\textsuperscript{77} These findings were confirmed in later studies from the same laboratory.\textsuperscript{78,79} Since the mice carrying the P301L mutation develop severe motor impairments as tau pathology advances, it is not possible to analyze memory improvement in these mice, as behavior tests commonly used for memory and cognition, like the Morris water maze, radial arm maze, or the T-maze require extensive motor movement. In a new double-transgenic mouse model, htau/PS1, which shows spatial memory deficits earlier by 12 months of age, it was possible to show that active tau-peptide immunization can prevent cognitive impairments, which was tested by two different maze tests and object recognition.\textsuperscript{79}

There has been only one report presenting an adverse effect of tau immunization in mice, in which the immunized mice developed a late form of experimentally induced autoimmune encephalitis similar to the autoimmune pathogenesis found in mice that had been immunized with myelin oligodendrocyte glycoprotein or myelin basic protein as myelin self-antigens. In this study, the mice had been immunized with full-length tau together with two strong inflammation-inducing substrates—complete Freund’s adjuvant (CFA) and pertussis toxin (PT)\textsuperscript{80}—because the researchers were interested to see the effects of maximal immune-system activation after immunization with a self-antigen. In a second study, this group used a phosphorylated tau peptide with
the same strong adjuvant combination, CFA and PT, and did not observe inflammatory or neurotoxic side effects, but found positive effects in increased microglial activity in brains from immunized mice and reduction of NFTs due to generation of anti-phospho-tau antibodies, which did not cross-react with full-length unhyperphosphorylated tau (the antigen used before), indicative of the importance of choosing the right target for the development of immunotherapeutic strategies.81

Passive immunization with well-characterized anti-tau antibodies, mAbs PHF, which react with phosphorylated Ser396 and Ser404 of the hyperphosphorylated tau protein as an early pathologic conformational epitope on tau confirmed the results seen in active immunization studies. Mice treated with these antibodies showed marked reductions in tau pathology, which was measured with biochemical methods and histology, as well as a significant delay in loss of motor-function decline which was assessed in behavioral testings.82,83

Similar to Aβ immunotherapy, there are several possibilities for antibodies to inhibit or slow the progression of disease. Antibodies might pass the blood–brain barrier and then enter neurons as well to modulate phosphorylation and/or degrade tau directly. It has been shown that tau-targeted immunization reduces the degree of tau phosphorylation in both young and aged mice,77,84 thereby reducing soluble hyperphosphorylated tau species that are toxic. Tau-targeted immunization may clear tau species that are involved in intercellular spreading of tau pathology and may prevent the initiation of tau aggregation.11 Anti-tau antibodies may help to support clearing functions by astrocytes as these were found to be activated in mice with high NFT burden following active immunization.84 Similar to the proposed peripheral sink mechanism for Aβ immunotherapy, anti-tau antibodies may facilitate tau clearance from the brain into the periphery, as an increase in tau concentrations was observed in blood from tau-immunized mice.85 These common antibody-action mechanisms are shown in Figure 2.

Links between these two pathologies

From pathophysiological analysis in mice and AD patients, it has been shown that Aβ accumulation precedes the formation of NFTs. It has also become clear that Aβ influences tau pathology and tau can influence Aβ pathology. Clearance of Aβ in humans or mice with immunotherapy had effects on tau pathology, and analysis of CSF levels for tau showed a reduction in patients that were positive-antibody responders in the stopped AN-1792 trial.36,86–89 In cell cultures of differentiated rat hippocampal neuronal cells, it was shown that Aβ42-oligomer administration directly led to tau phosphorylation at sites that discriminate among AD and non-AD subjects, which are Ser404, Thr231, Thr181, Ser202, and Thr205. This was found not only for synthetic Aβ oligomers but also for soluble extracts from AD brain containing the Aβ oligomers.90 A reduction of normal endogenous tau has been shown to ameliorate Aβ-induced dysfunction and early

AD immunotherapy

<table>
<thead>
<tr>
<th>Amyloid precursor protein</th>
<th>Tau protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased amyloidogenic processing</td>
<td>Intracellular kinases up</td>
</tr>
<tr>
<td>Aβ42 Aβ42 oligomers</td>
<td>Phoshatases down</td>
</tr>
<tr>
<td>Immunization</td>
<td>Hyperphosphorylated tau</td>
</tr>
<tr>
<td>Antibody production</td>
<td>Neurofibrillary tangles</td>
</tr>
<tr>
<td>1. Antibody-antigen binding in blood creates concentration gradient (peripheral sink)</td>
<td></td>
</tr>
<tr>
<td>2. Antibodies inhibit aggregation</td>
<td></td>
</tr>
<tr>
<td>3. Antibodies increase clearance of misfolded proteins by microglia</td>
<td></td>
</tr>
</tbody>
</table>

Figure 2 Common features of anti-amyloid beta (Aβ) and anti-tau antibodies. Both pathophysiological hallmarks of Alzheimer’s disease (AD) are caused by overproduction, aggregation, and misfolding of brain self-antigens. Active and passive immunotherapy and the respective anti-Aβ and anti-tau antibodies share common features of antibody actions.
mortality in transgenic mice, and tau reduction may thus be an option to treat AD symptoms. Epileptic seizures occur spontaneously in transgenic mice that overexpress APP at synapses, and it has been shown that the reduction of tau can decrease the incidence and severity of pharmacologically induced seizures without changes in Aβ levels. Thus, tau somehow enables Aβ-induced neuronal dysfunction. In a recent study, it was shown how oligomeric Aβ induces the phosphorylation of tau at specific sites, which drives neurons abnormally into cell cycles without division (ectopic cell-cycle reentry), leading to cell death and neuron loss. The authors conclude that this might be one reason for the substantial neuronal cell loss in AD.

While the ongoing and planned clinical trials are all concentrated on reduction of Aβ brain levels, future studies might be needed to test whether targeting Aβ and tau simultaneously can further improve the therapeutic efficacy of immunotherapy for AD.

Acknowledgments
This study was funded by grants from the NIH/NIA Alzheimer’s Disease Center (P30AG12300-17), the Rudman Partnership, and the McCune Foundation.

Disclosure
DLW declares no conflicts of interest. RNR has received clinical trial research grants from Janssen Inc, Novartis, and Pfizer. He holds a US Patent for amyloid beta gene vaccines. He is also on the editorial board of the Journal of the American Medical Association (JAMA) and the editor of JAMA Neurology.

References


